Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) EBIT Margin (2016 - 2025)

Sanara MedTech (SMTI) has disclosed EBIT Margin for 15 consecutive years, with 31.8% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 2821.0% year-over-year to 31.8%, compared with a TTM value of 5.77% through Sep 2025, up 1072.0%, and an annual FY2024 reading of 7.75%, down 126.0% over the prior year.
  • EBIT Margin was 31.8% for Q3 2025 at Sanara MedTech, up from 0.12% in the prior quarter.
  • Across five years, EBIT Margin topped out at 31.8% in Q3 2025 and bottomed at 48.52% in Q4 2021.
  • Average EBIT Margin over 5 years is 13.56%, with a median of 11.85% recorded in 2023.
  • The sharpest move saw EBIT Margin crashed -3073bps in 2021, then surged 2821bps in 2025.
  • Year by year, EBIT Margin stood at 48.52% in 2021, then soared by 58bps to 20.39% in 2022, then soared by 94bps to 1.28% in 2023, then dropped by -12bps to 1.43% in 2024, then skyrocketed by 2331bps to 31.8% in 2025.
  • Business Quant data shows EBIT Margin for SMTI at 31.8% in Q3 2025, 0.12% in Q2 2025, and 8.88% in Q1 2025.